Literature DB >> 22196160

Cardiac models in drug discovery and development: a review.

Robert K Amanfu1, Jeffrey J Saucerman.   

Abstract

Cardiovascular diseases are among the leading causes of death in the developed world. Developing novel therapies for diseases like heart failure is crucial, but this is hampered by the high attrition rate in drug development. The withdrawal of drugs at the final hurdle of approval is mostly because of their unpredictable effects on normal cardiac rhythm. The advent of cardiac computational modeling in the last 5 decades has aided the understanding of heart function significantly. Recently, these models increasingly have been applied toward designing and understanding therapies for cardiac disease. This article will discuss how cellular models of electrophysiology, cell signaling, and metabolism have been used to investigate pharmacologic therapies for cardiac diseases including arrhythmia, ischemia, and heart failure.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22196160      PMCID: PMC3356786          DOI: 10.1615/critrevbiomedeng.v39.i5.30

Source DB:  PubMed          Journal:  Crit Rev Biomed Eng        ISSN: 0278-940X


  123 in total

1.  Cardiac action and pacemaker potentials based on the Hodgkin-Huxley equations.

Authors:  D NOBLE
Journal:  Nature       Date:  1960-11-05       Impact factor: 49.962

2.  Images in cardiovascular medicine. Himalayan T waves in the congenital long-QT syndrome.

Authors:  Dawood Darbar; Dan M Roden; Muhammed F Ali; Tao Yang; Mark S Wathen
Journal:  Circulation       Date:  2005-03-22       Impact factor: 29.690

3.  A comparison of monodomain and bidomain reaction-diffusion models for action potential propagation in the human heart.

Authors:  Mark Potse; Bruno Dubé; Jacques Richer; Alain Vinet; Ramesh M Gulrajani
Journal:  IEEE Trans Biomed Eng       Date:  2006-12       Impact factor: 4.538

4.  Rate dependence and regulation of action potential and calcium transient in a canine cardiac ventricular cell model.

Authors:  Thomas J Hund; Yoram Rudy
Journal:  Circulation       Date:  2004-10-25       Impact factor: 29.690

5.  Activation of human ether-a-go-go-related gene potassium channels by the diphenylurea 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643).

Authors:  Rie Schultz Hansen; Thomas Goldin Diness; Torsten Christ; Joachim Demnitz; Ursula Ravens; Søren-Peter Olesen; Morten Grunnet
Journal:  Mol Pharmacol       Date:  2005-10-11       Impact factor: 4.436

6.  Mechanism of action of a novel human ether-a-go-go-related gene channel activator.

Authors:  Oscar Casis; Søren-Peter Olesen; Michael C Sanguinetti
Journal:  Mol Pharmacol       Date:  2005-11-11       Impact factor: 4.436

7.  Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, I: experimental studies.

Authors:  B O'Rourke; D A Kass; G F Tomaselli; S Kääb; R Tunin; E Marbán
Journal:  Circ Res       Date:  1999-03-19       Impact factor: 17.367

Review 8.  Energy metabolism in heart failure.

Authors:  Renée Ventura-Clapier; Anne Garnier; Vladimir Veksler
Journal:  J Physiol       Date:  2003-12-05       Impact factor: 5.182

Review 9.  Proteomics of the heart: unraveling disease.

Authors:  Emma McGregor; Michael J Dunn
Journal:  Circ Res       Date:  2006-02-17       Impact factor: 17.367

Review 10.  What is the role of beta-adrenergic signaling in heart failure?

Authors:  Martin J Lohse; Stefan Engelhardt; Thomas Eschenhagen
Journal:  Circ Res       Date:  2003-11-14       Impact factor: 17.367

View more
  8 in total

Review 1.  Mathematical modeling of physiological systems: an essential tool for discovery.

Authors:  Patric Glynn; Sathya D Unudurthi; Thomas J Hund
Journal:  Life Sci       Date:  2014-07-23       Impact factor: 5.037

2.  Generating an in vitro 3D cell culture model from zebrafish larvae for heart research.

Authors:  Bianka Grunow; Lisa Mohamet; Holly A Shiels
Journal:  J Exp Biol       Date:  2015-02-24       Impact factor: 3.312

3.  Multi-scale Modeling of the Cardiovascular System: Disease Development, Progression, and Clinical Intervention.

Authors:  Yanhang Zhang; Victor H Barocas; Scott A Berceli; Colleen E Clancy; David M Eckmann; Marc Garbey; Ghassan S Kassab; Donna R Lochner; Andrew D McCulloch; Roger Tran-Son-Tay; Natalia A Trayanova
Journal:  Ann Biomed Eng       Date:  2016-05-02       Impact factor: 3.934

Review 4.  Implementation of quantitative and systems pharmacology in large pharma.

Authors:  S A G Visser; D P de Alwis; T Kerbusch; J A Stone; S R B Allerheiligen
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-10-22

5.  Network model-based screen for FDA-approved drugs affecting cardiac fibrosis.

Authors:  Angela C Zeigler; Anirudha S Chandrabhatla; Steven L Christiansen; Anders R Nelson; Jeffrey W Holmes; Jeffrey J Saucerman
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-02-27

Review 6.  Application of cardiac electrophysiology simulations to pro-arrhythmic safety testing.

Authors:  Gary R Mirams; Mark R Davies; Yi Cui; Peter Kohl; Denis Noble
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 7.  Combining wet and dry research: experience with model development for cardiac mechano-electric structure-function studies.

Authors:  T Alexander Quinn; Peter Kohl
Journal:  Cardiovasc Res       Date:  2013-01-17       Impact factor: 10.787

Review 8.  Humans Vary, So Cardiac Models Should Account for That Too!

Authors:  Barbara Wiśniowska; Zofia Tylutki; Sebastian Polak
Journal:  Front Physiol       Date:  2017-09-21       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.